141747-91-3

Upstream product

• 29261-44-7 2-(6-hydroxy-4-phenylpyridin-2-yl)phenyl 
• 53545-96-3 6-bromo-2,2-dimethylhexanenitrile 
• 29261-44-7 4,6-diphenyl-2-pyridone 

Downstream Products

• 141748-00-7 5-{1,1-dimethyl-5-[(4,6-diphenyl-2-pyridyl)oxy]pentyl}-[1H]-tetrazole 
• 206266-96-8 2-((tert-butoxy)carbonylamino)-N-(6-(4,6-diphenyl(2-pyridyloxy))-2,2-dimethylhexyl)-3-((fluoren-9-ylmethoxy)carbonylamino)propanamide 
• 206266-97-9 3-amino-2-((tert-butoxy)-carbonylamino)-N-(6-(4,6-diphenyl(2-pyridyloxy))-2,2-dimethylhexyl)propanamide 
• 206263-69-6 N-(6-(4,6-diphenyl(2-pyridyloxy))-2,2-dimethylhexyl)-3-pyridylformamide 
• 206265-17-0 6-[(4,6-diphenyl-2-pyridinyl)oxy]-2,2-dimethyl-1-hexylamine 

Relevant academic research and scientific papers

SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS

This invention relates to compounds having selective LTB 4 antagonist properties, compositions comprising said compounds and methods for the treatment of disorders involving LTB 4 agonist-mediated activity utilizing said compositions wherein the compounds

ω-alkanoic Acid Derivatives: A New Family of Potent and Orally Active LTB4 Antagonists

A series of ω-alkanoic acid derivatives was prepared which inhibited the binding of leukotriene B4 to its receptors on guinea pig spleen membranes and on human polymorphonuclear leukocytes (PMNs) and selectively ant